cytoxan......... 2 mg/kg orally days 1 to 14, then 100 mg daily.
adriamycin...... 20 mg/sqm IV day 1, then every 2 weeks.
fluorouracil.... 12 mg/kg IV days 1 to 3, then every 2 weeks.
vincristine..... 25 ug/kg IV day 1, then every 2 weeks times 3,
then every 4 weeks.
prednisone...... 0.75 mg/kg orally days 1 to 14, then 10 mg
FREQUENCY....... See drug schedules, above.
Muss HB. White DR. Richards F 2d. Cooper MR. Stuart JJ.
Jackson DV. Rhyne L. Spurr CL. Adriamycin versus
methotrexate in five-drug combination chemotherapy for
advanced breast cancer: a randomized trial. Cancer.
42(5):2141-8, 1978 Nov.
Adriamycin is of noteworthy efficacy in the treatment of
metastatic breast cancer. Its role in combination regimens is
under investigation. One hundred seventy-five women with
advanced breast cancer were entered into a prospectively
randomized trial comparing two five-drug regimens. Regimen
CMFVP consisted of cyclophosphamide (C), methotrexate (M),
5-fluorouracil (F), vincristine (V), and prednisone (P).
Regimen CAFVP was identical but substituted Adriamycin (A) for
methotrexate. Twenty-seven patients were disqualified; 148
were evaluable. With CMFVP the complete response rate (CR) was
11%, and the partial response rate (PR) was 46%; with CAFVP,
CR was 13% and PR was 45%. Duration of response tended to be
slightly longer for patients on the Adriamycin arm. The median
survival for CR and PR patients with CMFVP was 20.2 months,
which was shorter (p = .07) than the 33 month median survival
with CAFVP. Although statistical significance was not reached
at the 5% level, the increased survival of responders on the
Adriamycin regimen supports the data of other studies which
suggest that first line combination chemotherapy in advanced
breast cancer should include Adriamycin.